Washington, D.C. – Last week, the Rare Disease Company Coalition (RDCC), on behalf of 29 leading rare disease biotech companies, sent a letter to Department of Health and Human Services Secretary Robert F. Kennedy Jr. and the Trump Administration. The RDCC called on the Administration to prioritize the urgent needs of the 30 million Americans affected by rare disease and support policies that increase innovation and access to life-changing treatments.
The RDCC offers the following policy recommendations to ensure the 1 in 10 Americans living with a rare disease have access to safe and effective therapies:
The RDCC is ready to serve as a resource to policymakers to create a brighter and healthier future for American families impacted by rare diseases.
Read the full letter below.